GlassScriptPhysician profile
Peyman Naji
NPI 1720215429
$24,247.56
in general payments reported to CMS, 2019-2025
44 companies · $4,978 in 2025
The $4,978 reported for 2025 was more than what 83% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,846 · 2020: $1,141 · 2021: $2,666 · 2022: $2,692 · 2023: $4,112 · 2024: $4,813 · 2025: $4,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,207 · Consulting Fee: $3,940 · Travel and Lodging: $746 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,206.65 |
| Consulting Fee | $3,940.00 |
| Travel and Lodging | $746.04 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $8,352.85 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abiomed | $2,204.27 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,703.63 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,562.63 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,303.38 | 2020-2025 | |
| Medtronic Vascular, INC. | $1,266.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $873.79 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.44 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $618.95 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Biotronik INC. | $542.82 | 2019-2024 | Acticor 7 Vr-T Dx, Amvia Edge |
| Amgen INC. | $487.96 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $475.40 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $469.43 | 2019-2025 | |
| Abbott Laboratories | $464.34 | 2019-2025 | Cardiomems, Aveir |
| Novo Nordisk INC | $438.66 | 2021-2025 | Ozempic, Wegovy |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $402.51 | 2020-2024 | |
| Boston Scientific Corporation | $314.21 | 2021-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $247.16 | 2021-2025 | |
| Scpharmaceuticals INC. | $229.59 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $225.18 | 2023-2025 | Assure Wcd |
| Shockwave Medical, INC | $193.04 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| W. L. Gore & Associates, INC. | $125.42 | 2020-2021 | |
| Medtronic, INC. | $121.99 | 2021-2024 | Corevalve Evolut R, Venaseal |
| Amarin Pharma, INC. | $116.33 | 2019-2021 | |
| Cook Medical LLC | $114.39 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $96.34 | 2024 | Opsumit, Uptravi |
| Cvrx, INC. | $72.42 | 2020-2023 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $60.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $55.27 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $47.68 | 2023 | Inpefa |
| Arbor Pharmaceuticals, INC. | $45.92 | 2019 | |
| Bardy Diagnostics, INC. | $41.86 | 2021 | |
| Teleflex LLC | $28.10 | 2020 | |
| Terumo Medical Corporation | $27.82 | 2021 | |
| Ethicon US, LLC | $23.33 | 2019 | |
| Esperion Therapeutics, INC. | $23.12 | 2021 | |
| Lilly USA, LLC | $22.94 | 2025 | Zepbound, Mounjaro |
| Philips North America LLC | $22.09 | 2023 | |
| Astellas Pharma US INC | $19.76 | 2019 | |
| Cardiovascular Systems INC. | $18.95 | 2020 | |
| Angiodynamics, INC. | $18.18 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.16 | 2021 | |
| Cardiva Medical, INC. | $15.89 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Baxter Healthcare | $14.91 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peyman Naji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.